The value of immunoproteasome in acute myocardial infarction

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100045697

Enrollment

Unknown

Registered

2021-04-23

Start date

2021-04-30

Completion date

Unknown

Last updated

2021-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

acute myocardial infarction group:Nil

chronic total occlusion group:Nil

normal group:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The acute myocardial infarction group was selected as patients who underwent coronary angiography within 12 hours of the onset of acute myocardial infarction; 2. Chronic complete occlusion group was selected for patients with complete occlusive disease confirmed by coronary angiography, and the course of disease was 3 months or more; 3. In the normal group, patients with coronary angiography confirmed that the degree of vascular stenosis is less than or equal to 30%.

Exclusion criteria

Exclusion criteria: Patients with previous myocardial infarction, revascularization, cerebrovascular disease, tumor, surgery.

Design outcomes

Primary

Measure	Time frame
Immune proteasome;Immune proteasome 10;Immune proteasome7;	—

Countries

China

Contacts

Public ContactZhang Dongfeng

Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University

dongfengdoctor@outlook.com+86 15201119937

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026